BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
See today's BioWorld
Home
» Merck plumps anti-infective pipeline with $9.5B Cubist Pharmaceuticals acquisition
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Merck plumps anti-infective pipeline with $9.5B Cubist Pharmaceuticals acquisition
Dec. 9, 2014
By
Marie Powers
No Comments
With the PDUFA date for Cubist Pharmaceuticals Inc.'s potential blockbuster ceftolozane/tazobactam, branded Zerbaxa, just two weeks away, the Lexington, Mass.-based company became the latest target in a hot round of biopharma dealmaking.
BioWorld